Profile
Erik Wilander is a director who founded Aprovix AB in 2001.
Dr. Wilander is also the founder of Cellda AB.
Erik Wilander active positions
| Companies | Position | Start |
|---|---|---|
Aprovix AB
 Aprovix AB Medical SpecialtiesHealth Technology Aprovix AB develops, manufactures and supplies a device for early detection of pre-stages of cervix cancer. The company was founded by Erik Wilander in 2001 and is headquartered in Uppsala, Sweden. | Founder | 2000-12-31 |
Cellda AB
 Cellda AB Packaged SoftwareTechnology Services Cellda AB is a Swedish company founded in 2018 by Sören Nygren and Erik Wilander. The company is based in Uppsala, Sweden. Cellda® is a digital pathology company that aims to improve the accuracy and reproducibility of prostate cancer diagnosis. Cellda® provides automatic analysis of digital images of prostate biopsies to distinguish between normal and abnormal samples. The company's goal is to make the diagnosis of prostate cancer faster, more cost-effective, objective, and reproducible with the help of computerized image analysis of scanned microscope images from prostate samples. Accurate histological diagnosis of prostatic adenocarcinoma is an important issue worldwide, as it is the second most frequent malignancy after lung cancer in men worldwide, causing about 360,000 deaths. The CEO is Susanne Bredenberg. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Aprovix AB
Aprovix AB Medical SpecialtiesHealth Technology Aprovix AB develops, manufactures and supplies a device for early detection of pre-stages of cervix cancer. The company was founded by Erik Wilander in 2001 and is headquartered in Uppsala, Sweden. | Health Technology |
Cellda AB
Cellda AB Packaged SoftwareTechnology Services Cellda AB is a Swedish company founded in 2018 by Sören Nygren and Erik Wilander. The company is based in Uppsala, Sweden. Cellda® is a digital pathology company that aims to improve the accuracy and reproducibility of prostate cancer diagnosis. Cellda® provides automatic analysis of digital images of prostate biopsies to distinguish between normal and abnormal samples. The company's goal is to make the diagnosis of prostate cancer faster, more cost-effective, objective, and reproducible with the help of computerized image analysis of scanned microscope images from prostate samples. Accurate histological diagnosis of prostatic adenocarcinoma is an important issue worldwide, as it is the second most frequent malignancy after lung cancer in men worldwide, causing about 360,000 deaths. The CEO is Susanne Bredenberg. | Technology Services |
- Stock Market
- Insiders
- Erik Wilander
